| Symbol | MIRA |
|---|---|
| Name | MIRA PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 855 N WOLFE STREET,SUITE 601, BALTIMORE, Maryland, 21205, United States |
| Telephone | 737-289-0835 |
| Fax | — |
| — | |
| Website | https://www.mirapharmaceuticals.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001904286 |
| Description | MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Additional info from NASDAQ: |
(80% Positive) MIRA PHARMACEUTICALS, INC. (MIRA) Announces Enrollment Update for analog Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more(90% Positive) MIRA PHARMACEUTICALS, INC. (MIRA) Announces Clinical Development Update
Read moreDirector Del Giudice Matthew Paul 🟢 acquired 50.0K shares (1 derivative) of MIRA PHARMACEUTICALS, INC. (MIRA) at $0.94 Transaction Date: Jun 12, 2026 | Filing ID: 028712
Read moreDirector Whalen Matthew Pratt 🟢 acquired 50.0K shares (1 derivative) of MIRA PHARMACEUTICALS, INC. (MIRA) at $0.94 Transaction Date: Jun 12, 2026 | Filing ID: 028715
Read moreDirector MacPherson Edward Clouston 🟢 acquired 50.0K shares (1 derivative) of MIRA PHARMACEUTICALS, INC. (MIRA) at $0.94 Transaction Date: Jun 12, 2026 | Filing ID: 028713
Read moreNew Form 3 - MIRA PHARMACEUTICALS, INC. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001493152-26-027959 <b>Size:</b> 3 KB
Read more(70% Positive) MIRA PHARMACEUTICALS, INC. (MIRA) Provides Update on developed for chronic inflammatory pain
Read more(85% Positive) MIRA PHARMACEUTICALS, INC. (MIRA) Provides Update on potential for Ketamir-2 MIAMI
Read more(99% Neutral) MIRA PHARMACEUTICALS, INC. (MIRA) Announces Clinical Development Update
Read moreDirector Aminov Erez 🟢 acquired 83.5K shares (1 derivative) of MIRA PHARMACEUTICALS, INC. (MIRA) Transaction Date: Mar 30, 2026 | Filing ID: 014697
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| omega-3-carboxylic acids, 4g | DRUG | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01408303 |
| omega-3-carboxylic acids, 2g | DRUG | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01408303 |
| Olive oil, 4g | DRUG | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT01408303 |
| MRI 3T scanner | DEVICE | Phase PHASE1 | Esophageal Cancer | WITHDRAWN | NCT02689401 |
| IMO-2055 | DRUG | Phase PHASE2 | Renal Cell Carcinoma | COMPLETED | NCT00729053 |
| Saline placebo | DRUG | Phase PHASE1 | Hepatitis C | COMPLETED | NCT00728936 |
| Printed Handout | OTHER | Approved | Premature Birth | COMPLETED | NCT03225885 |
| Multimedia Information | OTHER | Approved | Premature Birth | COMPLETED | NCT03225885 |
| IMO-8400 | DRUG | Phase PHASE1 | Diffuse Large B Cell Lymphoma | COMPLETED | NCT02252146 |
| Intravenous normal saline | OTHER | Approved | IDA in the Post-bariatric Surgical Patient | WITHDRAWN | NCT03777514 |
| Oral vitamin C | OTHER | Approved | IDA in the Post-bariatric Surgical Patient | WITHDRAWN | NCT03777514 |
| IMO-8400 Dose Group 2 | DRUG | Phase PHASE2 | Dermatomyositis | COMPLETED | NCT02612857 |
| IMO-8400 Dose Group 1 | DRUG | Phase PHASE2 | Dermatomyositis | COMPLETED | NCT02612857 |
| Prasterone (DHEA) | DRUG | Phase PHASE3 | Vaginal Atrophy in Breast Cancer Patients | WITHDRAWN | NCT03740945 |
| Prasterone 6.5 mg (0.50%) Vaginal Insert | DRUG | Phase PHASE3 | Hypoactive Sexual Desire Disorder (HSDD) | WITHDRAWN | NCT03619005 |
| Placebo Vaginal Insert | DRUG | Phase PHASE3 | Hypoactive Sexual Desire Disorder (HSDD) | WITHDRAWN | NCT03619005 |
| Feraheme | DRUG | Phase PHASE1 | Anemia | TERMINATED | NCT02189889 |
| EPO | DRUG | Phase PHASE1 | Anemia | TERMINATED | NCT02189889 |
| Saline (0.9% sodium chloride) | DRUG | Phase PHASE2 | Malignant Melanoma | RECRUITING | NCT04126876 |
| Aspirin 81mg | DRUG | Phase PHASE4 | Pre-Eclampsia | UNKNOWN | NCT04908982 |
| Prasterone | DRUG | Phase PHASE3 | Recurrent Urinary Tract Infection | WITHDRAWN | NCT03854396 |
| 17P | DRUG | Phase PHASE3 | Pre-term Birth | COMPLETED | NCT03297216 |
| Magnetic Resonance Imaging | PROCEDURE | Phase PHASE2 | Brain Neoplasm | WITHDRAWN | NCT03234309 |
| Fluconazole 150mg capsule | DRUG | Phase PHASE3 | Recurrent Vulvovaginal Candidiasis | COMPLETED | NCT03840616 |
| Oteseconazole (VT-1161) 150mg capsule | DRUG | Phase PHASE3 | Recurrent Vulvovaginal Candidiasis | COMPLETED | NCT03840616 |
| Zofran | DRUG | Phase PHASE1 | Nausea | COMPLETED | NCT03973047 |
| AMAG-423 (digoxin immune fab) | BIOLOGICAL | Phase PHASE2 | Severe Preeclampsia | TERMINATED | NCT03008616 |
| placebo | DRUG | Phase PHASE1 | Anemia | COMPLETED | NCT00360425 |
| moxifloxacin | DRUG | Phase PHASE1 | Anemia | COMPLETED | NCT00360425 |
| ferumoxytol or oral iron | DRUG | Phase PHASE3 | Anemia | COMPLETED | NCT00255437 |
| IMO-8400 Regimen 4 | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT01899729 |
| Saline Placebo | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT01899729 |
| IMO-8400 Regimen 3 | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT01899729 |
| IMO-8400 Regimen 2 | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT01899729 |
| IMO-8400 Regimen 1 | DRUG | Phase PHASE2 | Plaque Psoriasis | COMPLETED | NCT01899729 |
| Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) | DRUG | Phase PHASE1 | Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women | COMPLETED | NCT02940522 |
| Oral Iron | DRUG | Phase PHASE3 | Iron Deficiency Anemia | TERMINATED | NCT01155375 |
| ASQ-3, Bayley III, Neurologic exam | DRUG | Preclinical | Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial | COMPLETED | NCT01146990 |
| Vehicle | DRUG | Phase PHASE3 | Preterm Birth | COMPLETED | NCT01004029 |
| Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL | DRUG | Phase PHASE3 | Preterm Birth | COMPLETED | NCT01004029 |
| Ipilimumab | DRUG | Phase PHASE2 | Metastatic Melanoma | COMPLETED | NCT02644967 |
| IMO-2125 | DRUG | Phase PHASE1 | Hepatitis C, Treatment Naïve, Genotype 1 Patients | COMPLETED | NCT00990938 |
| ABBV-181 | DRUG | Phase PHASE1 | Advanced Solid Tumors Cancer | COMPLETED | NCT04196283 |
| Nab-paclitaxel | DRUG | Phase PHASE1 | Advanced Solid Tumors Cancer | COMPLETED | NCT04196283 |
| Tilsotolimod | DRUG | Phase PHASE2 | Malignant Melanoma | RECRUITING | NCT04126876 |
| ABBV-368 | DRUG | Phase PHASE1 | Advanced Solid Tumors Cancer | COMPLETED | NCT04196283 |
| FCM | DRUG | Phase PHASE3 | Iron Deficiency Anemia | COMPLETED | NCT02694978 |
| Iron Sucrose | DRUG | Phase PHASE2 | Iron Deficiency | COMPLETED | NCT01052779 |
| 17-Hydroxyprogesterone Caproate 275 mg SC Dose | DRUG | Preclinical | Preterm Birth | TERMINATED | NCT04183452 |
| 17-Hydroxyprogesterone Caproate 250 mg IM Dose | DRUG | Preclinical | Preterm Birth | TERMINATED | NCT04183452 |
| Ferrous Sulfate | DRUG | Phase PHASE4 | Anemia, Iron Deficiency | RECRUITING | NCT04205266 |
| Ferrous sulfate | DRUG | Approved | IDA in the Post-bariatric Surgical Patient | WITHDRAWN | NCT03777514 |
| Ferumoxytol intravenous | DRUG | Phase PHASE2 | Restless Legs Syndrome | COMPLETED | NCT02499354 |
| Bremelanotide | DRUG | Phase PHASE1 | Nausea | COMPLETED | NCT03973047 |
| Iron sucrose | DRUG | Phase PHASE3 | Iron Deficiency Anemia | RECRUITING | NCT03893045 |
| Point-of-Care Coagulometer (investigational device) | DEVICE | Phase PHASE2 | Healthy | TERMINATED | NCT04593784 |
| Ciraparantag | DRUG | Phase PHASE2 | Healthy | TERMINATED | NCT04593784 |
| IMB-1018972 | DRUG | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT04826159 |
| Vitamin C | DRUG | Phase PHASE3 | Iron Deficiency Anemia | RECRUITING | NCT04268849 |
| Ferrous sulfate tablets | DRUG | Phase PHASE3 | Iron Deficiency Anemia | RECRUITING | NCT04268849 |
| Saline | DRUG | Phase PHASE1 | Hepatitis C, Treatment Naïve, Genotype 1 Patients | COMPLETED | NCT00990938 |
| Ferumoxytol | DRUG | Phase PHASE1 | Esophageal Cancer | WITHDRAWN | NCT02689401 |
| ferumoxytol | DRUG | Phase PHASE2 | Peripheral Arterial Disease (PAD) | UNKNOWN | NCT00707876 |
| Placebo | DRUG | Phase PHASE2 | Dermatomyositis | COMPLETED | NCT02612857 |
| Oteseconazole (VT-1161) | DRUG | Phase PHASE3 | Recurrent Vulvovaginal Candidiasis | COMPLETED | NCT03562156 |